Home/Pipeline/AHPBA IRE Registry

AHPBA IRE Registry

Pancreatic Cancer

Post-Market RegistryActive

Key Facts

Indication
Pancreatic Cancer
Phase
Post-Market Registry
Status
Active
Company

About AngioDynamics

AngioDynamics is a publicly traded medical device company with a mission to improve patient lives by providing innovative, minimally invasive tools for treating peripheral vascular disease and cancer. The company has strategically evolved from a broad vascular access provider into a focused innovator, building a diversified technology portfolio through R&D and acquisitions. Its current strategy centers on commercializing and expanding the clinical evidence for its three core platforms—Auryon, AlphaVac, and NanoKnife—while navigating a competitive landscape and managing the financial and operational challenges of a mid-cap device maker.

View full company profile

Therapeutic Areas

Other Pancreatic Cancer Drugs

DrugCompanyPhase
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
HBM9027Harbour BioMedPhase 1
Small-Molecule TherapeuticAIkido LabsPre-clinical
SIMBs + ImmunotherapyAdvanced MicrobubblesPre-clinical
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Pritumumab (PTB)Nascent BiotechPhase II (Planned)
Pancreatic Cancer TestMosaique DiagnosticDevelopment
Iontophoretic SystemContinuity BiosciencesPre-clinical
Lixumistat (IM156)ImmunoMet TherapeuticsPhase 1b
Electron IORTIntraop MedicalApproved